Latest News

24 June 2021

Infinity BiologiX and Cytox collaborate to provide new genetic test to predict the risk of cognitive decline due to Alzheimer’s Disease

Powered by Cytox’s genoSCORE, the new test enables physicians to support patients with lifestyle changes, and guide possible use of drug therapy, to delay the onset of disease symptoms

PISCATAWAY, N.J. & OXFORD, England & MANCHESTER, England--()--Today, Infinity BiologiX, LLC (IBX) and Cytox Ltd, announce a collaboration to provide a new, non-invasive, genetic test that can predict the risk of cognitive decline due to Alzheimer’s through a simple saliva or blood sample. The product is anticipated to be available to physicians in the coming months.

Physicians can use the genoSCORE test to assess patients before symptoms arise, and prior to invasive cerebrospinal fluid (CSF) testing or expensive scanning techniques. Furthermore, the test’s simplicity of use enables elderly and vulnerable patients not able to attend healthcare settings, to provide a sample from home.

Dr. Richard Pither, CEO of Cytox, commented: “Alzheimer’s disease affects over 46 million people in the world1. We see this new test as a powerful tool to enable physicians to make immediate decisions about their patients’ risk of cognitive decline due to Alzheimer’s disease, and guide them towards effective lifestyle and therapeutic interventions that can have a significant impact on delaying the onset of disease symptoms and cognitive decline2. We are delighted to be working with IBX, a leading provider of laboratory tests that can bring this new product to US physicians and their patients.”

Robin Grimwood, IBX CEO, explained, “We see this agreement for the sale and distribution of the genoSCORE-powered test as a critical collaboration in line with our mission to understand the genetic causes of common, complex diseases, such as Alzheimer’s, and to discover diagnoses, treatments and, support the development of new, effective therapeutic interventions for these diseases.”

From our portfolio



CLYZ Labs are developing a testing service to select the best drug therapy for personalised cance...

viewview our portfolio

Our Team

Hamish Graham

view complete team

Contact us

Binder House
7 Narborough Wood Park
Desford Road
LE19 4XT

Tel: 0116 238 8200